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Summary 
Many novel therapeutic options for depression exist which are either not mentioned in clinical 
guidelines or recommended only for use in highly specialist services.  The challenge faced by 
clinicians is when it might be appropriate to consider such ‘non-standard’ interventions.  This 
analysis proposes a framework to aid this decision. 
Introduction 
There are numerous effective psychological therapies and drug treatments for the management 
of major depressive disorder (MDD) and guidelines for their use (e.g. those from the UK’s 
National Institute for Health and Care Excellence (NICE)1 or British Association for 
Psychopharmacology (BAP)2).  However, a major challenge is improving the management of 
MDD patients who do not experience full or sustained remission of symptoms with standard, 
guideline recommended, treatments or who cannot tolerate them.  A major issue is that many 
of the recommended treatments have similar mechanisms of action and in naturalistic studies 
there appears to be minimal difference in effectiveness between them.1,2  In addition, duration 
of depression is associated with worse outcomes,3 including social breakdown such as loss of 
job or relationship4 which in themselves can become barriers to recovery.  Fortunately, many 
alternative treatments, with potentially different mechanisms of action, exist which are either 
currently not included in guidelines or are only recommended for use in specialist services – 
we refer to these as ‘non-standard’.  These interventions are characterised by having a more 
limited evidence base to support their use, being associated with greater risks or invasiveness, 
and/or being more costly than standard treatments.  The important clinical question is when to 
consider them for a particular patient. 
Problems and possible solutions 
The answer to the question is in some ways simple.  If the probability of responding to (or 
tolerating) a further standard treatment is very low then a case can be made for using a non-
standard treatment.  However, the evidence based from which to draw such conclusions is far 
from ideal.  Studies vary in their definitions of degree of treatment resistance necessary for 
inclusion.  For example, the data supporting the use of quetiapine augmentation of 
antidepressants was obtained in studies of patients who had had a sub-optimal response to their 
first, or possibly second, antidepressant.5  Inclusion in some studies is defined as much by 
chronicity as lack of treatment response.6  What studies there are tend to relate to patients who 
are treatment non-responsive rather than partially responsive, or to patients who have strong 
preferences for some treatments but not others.7  Overall, it is also important to note, there is 
little robust evidence from prospective sequential RCTs for the efficacy of options beyond third 
or fourth sequential treatments.8 
One possible solution is to consider non-standard interventions only when all standard ones 
have been tried and failed.  However, adequate trials of all possible combinations of 
pharmacotherapy alone would take literally decades.  The evidence base does not support this 
strategy.  Naturalistic data suggests that the response rate of patients with chronic TRD to 
standard interventions is only around 10% over one year.6  Further evidence suggests that the 
duration of untreated depression has a negative impact on eventual response.3  It is therefore 
clinically questionable to cycle endlessly through pharmacologically similar strategies.9 
An alternative option is to use a ‘threshold’ approach.  Conway and colleagues proposed 
‘treatment resistant depression’ (TRD) be divided into “stage I” defined as failure of two 
interventions (medication or psychotherapy) and “stage II” defined as failure of three 
interventions.9  They propose that less invasive non-standard interventions could be considered 
for “stage I TRD” and more invasive interventions (e.g. vagal nerve stimulation (VNS) or deep 
brain stimulation (DBS)) for “stage II TRD”.9  This threshold would allow for DBS for a patient 
after failure of 20 mg of fluoxetine and 20mg of citalopram, both prescribed over 6 weeks, and 
8 sessions of cognitive behaviour therapy (CBT).  We believe this is premature.  This also 
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illustrates the problem of a simple threshold approach with the challenge being how to find the 
best balance between timely access to alternative treatments versus unnecessary exposure to 
risky/expensive interventions.  The threshold for different interventions is also likely to be 
different with, for example, the threshold for ablative neurosurgery being substantially higher 
than for a well-tolerated and safe non-standard medication.  There are also a myriad of patient 
and illness factors that will also influence when a particular treatment might be deemed 
appropriate. 
Rather than a simple threshold we suggest a more nuanced approach with a defined reference 
point, which we refer to as ‘multi-therapy resistant MDD’ (MTR-MDD), to help guide 
clinicians, patients and commissioners. 
‘Multi-therapy resistant-MDD (MTR-MDD)’ 
The criteria proposed for MTR-MDD (outlined in Table 1), for the reasons outlined above, are 
based more on consensus than clear cut evidence.  They have been developed by clinicians 
drawn from primary care, secondary care and specialist services (see the authors’ disclosure 
statements), including individuals with personal experience of MDD. 
The intention is that the MTR-MDD criteria can be broken down into its various component 
parts to help guide discussions between clinicians, patients, and commissioners about when it 
may be reasonable to consider non-standard intervention.  In totality the criteria provide 
something of a ‘back stop’ – if a patient meets all of the criteria but has not been considered 
for non-standard treatment, then the question “why not?” should be asked.  We do not posit 
that MTR-MDD defines a specific sub-group of patients with MDD that may be characterised, 
for example, by a specific biology.  However, the categorisation is potentially of use in research 
for stratification in trials of patients with particularly difficult to treat illness. 
The term ‘multiple-therapy-resistant-MDD’ has been chosen to reflect that: several 
interventions (more than two) must have failed to produce or maintain a response, or have been 
intolerable;  non-pharmacological interventions should also have been tried and been 
ineffective or intolerable; and that the criteria are specific to MDD.   
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Table 1:  Proposed criteria for MTR-MDD 
The Patient:  Diagnosed with MDD (using the Diagnostic and Statistical Manual, 5th edition (DSM-
5)) 
Their depression:  MDD of at least moderate severity. 
Their treatment: 
 Psychotherapy.  At least two trials of structured, evidence-supported psychological 
therapy.1  The trials should ideally each be of a different modality and provided by a 
different therapist.  In both cases, the clinician should assure themselves that the patient 
has received a structured course of therapy delivered by an experienced therapist with 
whom the patient had a good therapeutic relationship.  Ideally, at least one of the trials 
should have been of at least 16 hours duration and at least one trial should have been given 
in combination with pharmacotherapy. 
 Antidepressants.  Four adequate trials of antidepressants.  There is little consensus with 
regards how antidepressants should be divided into different ‘classes’ and how important 
it is that drugs from different classes are trialed.  However, it is recommended that the trials 
should not all be from the same class of drugs and that at least two trials are using 
antidepressants that are viewed as being potentially more efficacious in severe depression 
and/or compared to other antidepressants, for example as listed by BAP guidelines 
(clomipramine, venlafaxine (⩾150 mg), escitalopram (20 mg), sertraline, amitriptyline or 
mirtazapine).2  We would also recommend consideration of a traditional MAOI (e.g. 
phenelzine), especially for patients with atypical symptoms. 
 Pharmacological augmentation.  At least two adequate trials of an evidence based 
augmentation/combination agent given in combination with an antidepressant.  Ideally 
these should both be agents listed as first line options in BAP Guidelines (lithium (ideally 
with a plasma level of 0.6 – 1.0 mmol/l), quetiapine and aripiprazole).2 
 ECT.  A trial of ECT (at least 8 treatments, and ideally bilateral if tolerated).  
For all treatments:  The requirement for a treatment may be waived if there is a recognised 
contraindication or the patient has, despite extensive discussions and the provision of information, 
declined it, or there have been well-documented adverse effects that have limited tolerability.  This 
applies to ECT, psychotherapy and medication. 
 
Given evidence for possible greater efficacy of a structured psychological treatment in combination 
with medication10,11, a period of combined treatment, possibly over a period of 9-15 months, is 
recommended.   
 
 
The full MTR-MDD criteria are met if there has been a failure to respond, achieve remission, 
maintain a response/remission or tolerate all the treatments listed in table 1.  For many 
patients, it can be difficult distinguishing discrete episodes.  It is inappropriate to re-trial 
medications that have failed in previous episodes unless the patient describes previous non-
adherence and willingness to retry.  As a result, these failures will usually be defined over the 
life-time of the patient. 
As in any area of medicine, non-response to an intervention should lead to a re-appraisal of the 
diagnosis.12  Alternative primary diagnoses such as bipolar disorder should be carefully 
excluded.  Comorbidities that may be contributing to the resistant nature of the MDD, such as 
substance use disorders, personality disorders, anxiety disorder and attention deficit and 
hyperactivity disorder (ADHD), should be identified and treated vigorously.  Similarly, 
psychosocial maintain factors should be addressed where possible.  However, the presence of 
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such comorbidity does not negate a patient meeting criteria and hence consideration being 
given to non-standard interventions. 
For all medications, an adequate trial is one where the clinician is confident (based on clinical 
judgement and patient history) that the patient has been adherent to a maximum licensed, or 
maximum-tolerated, dose for an adequate period of time.  In the case of a maximum tolerated 
dose, this must be a dose equivalent or higher than the generally regarded minimal therapeutic 
dose (e.g. as defined in the drug license).  If a patient is not able to tolerate a minimum 
therapeutic dose, then the trial would be deemed to have failed on the basis of intolerance. 
First and second line treatment trial durations are recommended to be 4-6 weeks, but for 
patients with resistant depression longer trials are recommended.1,2  We recommend that at 
least one, and ideally two trials of antidepressants have been used for a minimum duration of 
eight weeks at maximum or maximum tolerated doses based on the need to balance ‘efficiency’ 
of a trial (shortest reasonable time) with the need to confidently exclude a potential response.  
The duration of augmentation trials is rarely described in guidelines.  RCT data suggests a 
relatively rapid response to some agents, for example antipsychotic augmentation (e.g. 
quetiapine5), while other strategies may take longer at least in part due to the time needed to 
reach a therapeutic level (e.g. lithium).  Nevertheless, we would recommend a minimum of a 
four weeks, and ideally eight weeks, at a therapeutic dose, for augmentation trials. 
With regards to non-tolerance, in almost all circumstances, clinicians should endeavour to 
establish that all reasonable efforts have been taken to ensure that the patient can tolerate at 
least the minimum therapeutic dose.  This may require extended dose titration periods, using 
preparations that allow starting at very low doses, the use of other medications (such as 
benzodiazepines for example when using an activating drug such as aripiprazole) and frequent 
review.  In many situations, the clinician should recommend at least one other drug from the 
same drug class to ensure that intolerance is class rather than drug-specific.   
Determining the adequacy of a course of psychotherapy may be more difficult, as factors not 
always directly-related to the patient or their illness have been demonstrated to impact on 
outcome, including therapeutic alliance, therapist adherence to the therapeutic modality and 
match between patient and therapeutic modality.13-15  Some patients need several months of 
preparation by clinicians or psychotherapists to develop the psychological mindedness to 
benefit from a course of any psychotherapy.  These considerations and assessment of past 
psychotherapy may of itself be a justification for seeking an expert psychotherapy opinion. 
The rationale for including ECT as a requirement in the MTR-MDD criteria is that ECT is, for 
most people, a choice that offers a high chance of improvement16 and acceptable levels of risk 
compared with more advanced and/or less evidence based options.  However, a failure of ECT 
to lead to a maintained response despite antidepressant prophylaxis, or a refusal/inability to 
undergo a trial of ECT, would be an appropriate prompt to consider alternative interventions 
with patients, especially if they meet MTR-MDD criteria. 
Using the MTR-MDD Criteria to guide the use of non-standard treatments 
Non-standard interventions can be considered to exist on a spectrum.  At one end, there are 
those which have a relatively strong evidence base to support their use in MDD, are easy to 
implement, well tolerated, non-invasive and relatively cheap.  At the other end, interventions 
have more limited evidence to support them, their use is more complex to undertake, they are 
associated with more risks or invasiveness, and/or they are of higher costs than standard 
interventions.  The position of an intervention on the spectrum also depends on its regional and 
national availability and the expertise of the clinician(s) using it.  Infrequently used 
interventions are more likely to be appropriate for specialised centres.  This, as well as other 
factors, is prone to change over time as more evidence is acquired.   
Consideration of these issues can help decisions about the potential position in the treatment 
algorithm of specific non-standard interventions.  Interventions supported by RCT data, well 
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tolerated and of a similar cost to standard treatments are likely to be used early on.  It may well 
be totally inappropriate to wait till a patient has a duration of illness of two years and/or has 
had three episodes of illness.  When such interventions are used will be determined primarily 
by clinician expertise and local availability. 
The threshold for some non-standard interventions may be determined by individual elements 
of the MTR-MDD criteria.  For example, transdermal selegiline has been shown to be 
particularly effective in patients with atypical depression,17 but in many parts of the world is 
extremely expensive to acquire.  As a result, it is probably reasonable that the MTR-MDD 
antidepressant criteria are met, including that a standard monoamine oxidase inhibitor (MAOI) 
that irreversibly blocks MAO-B is tried first.  Similarly, the complex psychotherapy Cognitive 
Behavioural Analysis System of Psychotherapy (CBASP) which has data supporting its use in 
treatment resistant MDD18 but which is non-standard primarily because of limited availability, 
is likely to only be considered if a patient meets the MTR-MDD psychotherapy criteria. 
Modafinil is not included in NICE depression guidelines,1 though it is mentioned as an option 
for use in specialist centres in BAP guidelines2 on the basis of four RCTs conducted in 
primarily non-treatment resistant MDD patients.19  In general it is well tolerated and can be 
combined with most antidepressants.  It is therefore at the more benign end of the non-standard 
therapy spectra.  It would seem reasonable to consider this if the MTR-MDD criteria for 
pharmacological augmentation are met.  Conversely, pramipexole, which is supported by just 
two conflicting RCTs20 and is more complex to use (due to the potential for impulse control 
disorders such as gambling)21 is likely to be considered only after a range of interventions have 
been unsuccessful i.e. beyond MTR-MDD augmentation criteria.  Further along the spectra, 
Intravenous ketamine, which is supported by a number of studies but which is also associated 
with risk, invasiveness and limited duration of effect22 is likely to only be used if broader MTR-
MDD criteria are met. 
There are an increasing number of non-drug physical treatments for MDD that vary in their 
degree of invasiveness.  Transcranial magnetic stimulation (TMS) is well tolerated and 
supported by NICE recommendations.23  Hence by our definitions it is a ‘standard’ intervention 
though its use is limited by availability.  It may be considered before ECT in the treatment 
algorithm for some patients at less immediate risk.  Conversely, VNS has been reviewed by 
NICE and recommended for use only “with special arrangements for clinical governance, 
consent and audit or research”.24  It might be appropriate to consider this if ECT has been 
considered inappropriate, unacceptable or it has led to an inadequate response.  Given its cost 
and limited availability it is also likely that patients will meet the other criteria MTR-MDD 
criteria.  The full MTR-MDD criteria are likely to be the bare minimum for consideration of 
anterior cingulotomy or other neurosurgical procedure, though the concern is that even for this 
highly invasive irreversible intervention there is often currently too long a delay before a 
patient is considered for this. 
Clearly an additional factor that influences where an intervention is placed in the algorithm is 
the patient.  For example, a concern about medication may lead to the use of a non-invasive 
relatively cheap non-drug physical intervention such as TMS early on.  Alternatively the 
clinical characteristics of a patient may influence choice.  With regards to standard 
interventions an example would be the use of ECT early on for patients with psychotic 
depression or marked psychomotor retardation.  Similarly, VNS might be considered for 
patients with highly recurrent depression despite ongoing prophylactic medication.25  
Discussion 
With the welcome burgeoning of novel non-standard interventions, the question is where in the 
treatment algorithm they should be used.  The appropriate place will vary between patients and 
interventions.  Clinical decisions regarding this are a complex interplay between various factors 
such as: the patient’s clinical state; research evidence; patient preference and expectations; and 
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the expertise and experience of the clinician.  A significant concern is that non-standard 
interventions are only brought into consideration much later than might be appropriate and that 
this is to the detriment of the patient, though they may also be used inappropriately early in 
some situations.  We argue that the framework and MTR-MDD criteria described in this paper 
should complement clinical expertise rather than replace it, to act as a reference point around 
which to gauge when it is clinically appropriate to use non-standard interventions.  We believe 
that a patient meeting all of the MTR-MDD criteria should be considered for non-standard 
treatment if this has not already happened.  The criteria also act as a prompt for clinicians with 
regards standard interventions.  Whether MTR-MDD criteria are appropriate for all age groups, 
including adolescents, is an open question.  At the very least we hope that this analysis piece 
prompts debate around these issues. 
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